other material
confidence high
sentiment positive
materiality 0.60
Valion Bio completes oral mucosal Entolimod formulation work with Shear Kershman Laboratories
Valion Bio, Inc.
- Valion Bio and Shear Kershman Laboratories completed formulation work for an oral mucosal Entolimod using SKL's BioViscid drug-delivery platform.
- The program is a potential second, needle-free pathway alongside Valion's injectable Entolimod; next study will test measurable systemic exposure to Entolimod.
- Valion estimates U.S. doses for oral mucosal Entolimod could be 10 to 40 times its injectable program, assuming supply to ~2.0M military, 1.0M firefighters and 790,000 law enforcement officers.
- Valion holds an exclusive worldwide license from Statera Biopharma to develop and commercialize Entolimod for acute radiation syndrome and radiation-induced neutropenia.
- The release says all FDA-approved products address only hematopoietic ARS, and no treatment is approved for the gastrointestinal indication.